{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T03:09:55Z","timestamp":1774408195838,"version":"3.50.1"},"reference-count":76,"publisher":"American Association for Laboratory Animal Science","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are the major prevalent liver diseases and growing public health problems worldwide. Because MASLD\/MASH is known as a risk for progression to cirrhosis and development of hepatocellular carcinoma, therapeutic approaches and biomarkers that reflect the presence and progression of the disease are needed. In recent years, the usefulness of serum L-FABP levels has been reported for monitoring of hepatocellular damage in various liver diseases including MASLD\/MASH in humans. Furthermore, it is reported that hepatic L-FABP is a potential therapeutic target. The purpose of this study was to validate the usefulness of serum L-FABP as a liver damage biomarker in the mouse model of MASLD\/MASH and to evaluate the function of L-FABP in the pathogenesis of MASLD\/MASH. First, we evaluated the changes in serum L-FABP as a liver damage biomarker using a mouse model of MASLD\/MASH fed a choline-deficient, methionine-lowered, amino acid-defined, high-fat diet. The results demonstrated that serum L-FABP levels in the MASLD\/MASH model continuously increased with the progression of steatosis and correlated with histopathologic changes. Serum L-FABP may be a useful biomarker for liver disease with respect to translational research bridging between animal models and human clinical research. Further, we showed that in human L-FABP chromosomal transgenic mice L-FABP had a suppressive effect on the gene expression associated with oxidative stress, fibrosis, and inflammation in the MASLD\/MASH model. L-FABP is not only a biomarker in the blood but also has the functional aspect of hepatoprotection against MASLD\/MASH.<\/jats:p>","DOI":"10.30802\/aalas-jaalas-25-003","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T20:01:46Z","timestamp":1747339306000},"page":"952-961","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Serum L-FABP as a Biomarker and Hepatoprotective Effect of L-FABP Using Wild-Type and Human L-FABP Chromosome Transgenic Mice"],"prefix":"10.30802","volume":"64","author":[{"given":"Keiichi","family":"Ohata","sequence":"first","affiliation":[{"name":"Department of Nutritional Science and Food Safety, Faculty of Applied Biosciences, Tokyo University of Agriculture, Setagaya-Ku, Tokyo, Japan;"},{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan;"},{"name":"CMIC Holdings Co, Ltd, Minato-ku, Tokyo, Japan;"},{"name":"Timewell Medical Co, Ltd, Bunkyo-ku, Tokyo, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanjiro","family":"Ryu","sequence":"additional","affiliation":[{"name":"Department of Food and Nutritional Science, Graduate School of Agriculture, Tokyo University of Agriculture, Setagaya-Ku, Tokyo, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinuko","family":"Uno","sequence":"additional","affiliation":[{"name":"Laboratory of Animal Physiology and Functional Anatomy, Graduate School of Agriculture, Kyoto University, Kyoto, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soon Hui","family":"Teoh","sequence":"additional","affiliation":[{"name":"Department of Food and Nutritional Science, Graduate School of Agriculture, Tokyo University of Agriculture, Setagaya-Ku, Tokyo, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Sugaya","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan;"},{"name":"Timewell Medical Co, Ltd, Bunkyo-ku, Tokyo, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuko","family":"Kamijo-Ikemori","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan;"},{"name":"Department of Anatomy, St. Marianna University School of Medicine, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Suzuki-Kemuriyama","sequence":"additional","affiliation":[{"name":"Department of Nutritional Science and Food Safety, Faculty of Applied Biosciences, Tokyo University of Agriculture, Setagaya-Ku, Tokyo, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiro","family":"Miyajima","sequence":"additional","affiliation":[{"name":"Department of Nutritional Science and Food Safety, Faculty of Applied Biosciences, Tokyo University of Agriculture, Setagaya-Ku, Tokyo, Japan;"},{"name":"Department of Food and Nutritional Science, Graduate School of Agriculture, Tokyo University of Agriculture, Setagaya-Ku, Tokyo, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"12258","reference":[{"issue":"4","key":"bib1","series-title":"J Hepatol.","first-page":"896","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030","volume":"69","author":"Estes C","year":"2018","unstructured":"Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J Hepatol. 2018;69(4):896\u2013904."},{"key":"bib2","series-title":"Metabolism.","first-page":"155835","article-title":"Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges","volume":"154","author":"Kokkorakis M","year":"2024","unstructured":"Kokkorakis M, Boutari C, Hill MA, et al. Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges. Metabolism. 2024;154:155835."},{"issue":"1\u20132","key":"bib3","series-title":"Mol Cell Biochem.","first-page":"225","article-title":"Liver fatty acid-binding protein in two cases of human lipid storage","volume":"98","author":"Vergani L","year":"1990","unstructured":"Vergani L, Fanin M, Martinuzzi A, et al. Liver fatty acid-binding protein in two cases of human lipid storage. Mol Cell Biochem. 1990;98(1\u20132):225\u2013230."},{"issue":"4","key":"bib4","series-title":"Hepatology.","first-page":"871","article-title":"Antioxidative function of L-FABP in L-FABP stable transfected Chang liver cells","volume":"42","author":"Wang G","year":"2005","unstructured":"Wang G, Gong Y, Anderson J, et al. Antioxidative function of L-FABP in L-FABP stable transfected Chang liver cells. Hepatology. 2005;42(4):871\u2013879."},{"issue":"1","key":"bib5","series-title":"Eur J Pharmacol.","first-page":"61","article-title":"Expression and antioxidant function of liver fatty acid binding protein in normal and bile-duct ligated rats","volume":"560","author":"Wang G","year":"2007","unstructured":"Wang G, Shen H, Rajaraman G, et al. Expression and antioxidant function of liver fatty acid binding protein in normal and bile-duct ligated rats. Eur J Pharmacol. 2007;560(1):61\u201368."},{"issue":"125","key":"bib6","series-title":"Hepatogastroenterology.","first-page":"1095","article-title":"Serum liver fatty acid binding protein shows good correlation with liver histology in NASH","volume":"60","author":"\u00d6zenirler S","year":"2013","unstructured":"\u00d6zenirler S, Degertekin CK, Erkan G, et al. Serum liver fatty acid binding protein shows good correlation with liver histology in NASH. Hepatogastroenterology. 2013;60(125):1095\u20131100."},{"issue":"1-2","key":"bib7","series-title":"Wien Klin Wochenschr.","first-page":"48","article-title":"Liver fatty acid-binding protein as a diagnostic marker for non-alcoholic fatty liver disease","volume":"128","author":"Akbal E","year":"2016","unstructured":"Akbal E, Ko\u00e7ak E, Aky\u00fcrek O, K\u00f6kl\u00fc S, Batgi H, \u015eenes M. Liver fatty acid-binding protein as a diagnostic marker for non-alcoholic fatty liver disease. Wien Klin Wochenschr. 2016;128(1-2):48\u201352."},{"issue":"2","key":"bib8","series-title":"Int J Med Sci.","first-page":"182","article-title":"Circulating fatty acid-binding protein 1 (FABP1) and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus","volume":"17","author":"Lu Y-C","year":"2020","unstructured":"Lu Y-C, Chang C-C, Wang C-P, et al. Circulating fatty acid-binding protein 1 (FABP1) and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Int J Med Sci. 2020;17(2):182\u2013190."},{"issue":"1","key":"bib9","series-title":"Arch Med Res.","first-page":"34","article-title":"Liver fatty acid-binding protein is a diagnostic marker to detect liver injury due to chronic hepatitis C infection","volume":"44","author":"Akbal E","year":"2013","unstructured":"Akbal E, K\u00f6kl\u00fc S, Ko\u00e7ak E, et al. Liver fatty acid-binding protein is a diagnostic marker to detect liver injury due to chronic hepatitis C infection. Arch Med Res. 2013;44(1):34\u201338."},{"issue":"2","key":"bib10","series-title":"J Hepatol.","first-page":"337","article-title":"Randomized controlled trial analyzing the effect of 15 or 30 min intermittent Pringle maneuver on hepatocellular damage during liver surgery","volume":"55","author":"van den Broek MA","year":"2011","unstructured":"van den Broek MA, Bloemen JG, Dello SA, van de Poll MC, Olde Damink SW, Dejong CH. Randomized controlled trial analyzing the effect of 15 or 30 min intermittent Pringle maneuver on hepatocellular damage during liver surgery. J Hepatol. 2011;55(2):337\u2013345."},{"issue":"11","key":"bib11","series-title":"Clin Chem.","first-page":"2055","article-title":"Liver fatty acid-binding protein as a sensitive serum marker of acute hepatocellular damage in liver transplant recipients","volume":"48","author":"Pelsers MM","year":"2002","unstructured":"Pelsers MM, Morovat A, Alexander GJ, Hermens WT, Trull AK, Glatz JF. Liver fatty acid-binding protein as a sensitive serum marker of acute hepatocellular damage in liver transplant recipients. Clin Chem. 2002;48(11):2055\u20132057."},{"issue":"2","key":"bib12","series-title":"Hepatology.","first-page":"760","article-title":"Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort","volume":"69","author":"Church RJ","year":"2019","unstructured":"Church RJ, Kullak-Ublick GA, Aubrecht J, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort. Hepatology. 2019;69(2):760\u2013773."},{"issue":"3","key":"bib13","series-title":"Hepatology.","first-page":"938","article-title":"Elevated FABP1 serum levels are associated with poorer survival in acetaminophen-induced acute liver failure","volume":"65","author":"Karvellas CJ","year":"2017","unstructured":"Karvellas CJ, Speiser JL, Tremblay M, Lee WM, Rose CF, Group U, US Acute Liver Failure Study Group. Elevated FABP1 serum levels are associated with poorer survival in acetaminophen-induced acute liver failure. Hepatology. 2017;65(3):938\u2013949."},{"issue":"6","key":"bib14","series-title":"Hepatol Commun.","first-page":"825","article-title":"Serum liver-type fatty acid-binding protein is a possible prognostic factor in human chronic liver diseases from chronic hepatitis to liver cirrhosis and hepatocellular carcinoma","volume":"3","author":"Eguchi A","year":"2019","unstructured":"Eguchi A, Hasegawa H, Iwasa M, et al. Serum liver-type fatty acid-binding protein is a possible prognostic factor in human chronic liver diseases from chronic hepatitis to liver cirrhosis and hepatocellular carcinoma. Hepatol Commun. 2019;3(6):825\u2013837."},{"issue":"1","key":"bib15","series-title":"Pharm Res.","first-page":"89","article-title":"The role of elevated liver-type fatty acid-binding proteins in liver diseases","volume":"38","author":"Eguchi A","year":"2021","unstructured":"Eguchi A, Iwasa M. The role of elevated liver-type fatty acid-binding proteins in liver diseases. Pharm Res. 2021;38(1):89\u201395."},{"issue":"1","key":"bib16","series-title":"Transplant Proc.","first-page":"413","article-title":"Liver fatty acid-binding protein: an early and sensitive plasma marker of hepatocellular damage and a reliable predictor of graft viability after liver transplantation from non-heart-beating donors","volume":"37","author":"Monbaliu D","year":"2005","unstructured":"Monbaliu D, de Vries B, Crabb\u00e9 T, et al. Liver fatty acid-binding protein: an early and sensitive plasma marker of hepatocellular damage and a reliable predictor of graft viability after liver transplantation from non-heart-beating donors. Transplant Proc. 2005;37(1):413\u2013416."},{"issue":"2","key":"bib17","series-title":"Curr Health Sci J.","first-page":"115","article-title":"Liver fatty acid binding protein and hemojuvelin - potential biomarkers for liver function in rat model","volume":"41","author":"Bogdan M","year":"2015","unstructured":"Bogdan M, Silosi I, Surlin P, et al. Liver fatty acid binding protein and hemojuvelin - potential biomarkers for liver function in rat model. Curr Health Sci J. 2015;41(2):115\u2013120."},{"issue":"3","key":"bib18","series-title":"J Appl Toxicol.","first-page":"516","article-title":"Serum biomarkers of isoniazid-induced liver injury: aminotransferases are insufficient, and OPN, L-FABP and HMGB1 can be promising novel biomarkers","volume":"42","author":"Cheng X","year":"2022","unstructured":"Cheng X, Zhu J-L, Li Y, et al. Serum biomarkers of isoniazid-induced liver injury: aminotransferases are insufficient, and OPN, L-FABP and HMGB1 can be promising novel biomarkers. J Appl Toxicol. 2022;42(3):516\u2013528."},{"issue":"2","key":"bib19","series-title":"Int J Exp Pathol.","first-page":"93","article-title":"An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis","volume":"94","author":"Matsumoto M","year":"2013","unstructured":"Matsumoto M, Hada N, Sakamaki Y, et al. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. Int J Exp Pathol. 2013;94(2):93\u2013103."},{"issue":"4","key":"bib20","series-title":"Int J Exp Pathol.","first-page":"221","article-title":"Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet","volume":"98","author":"Ikawa-Yoshida A","year":"2017","unstructured":"Ikawa-Yoshida A, Matsuo S, Kato A, et al. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet. Int J Exp Pathol. 2017;98(4):221\u2013233."},{"issue":"4","key":"bib21","series-title":"Am J Pathol.","first-page":"1243","article-title":"Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules","volume":"165","author":"Kamijo A","year":"2004","unstructured":"Kamijo A, Sugaya T, Hikawa A, et al. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol. 2004;165(4):1243\u20131255."},{"issue":"4","key":"bib22","series-title":"Am J Physiol Renal Physiol.","first-page":"F669","article-title":"Urinary fatty acid-binding protein 1: an early predictive biomarker of kidney injury","volume":"296","author":"Noiri E","year":"2009","unstructured":"Noiri E, Doi K, Negishi K, et al. Urinary fatty acid-binding protein 1: an early predictive biomarker of kidney injury. Am J Physiol Renal Physiol. 2009;296(4):F669\u2013F679."},{"issue":"6","key":"bib23","series-title":"Nephrology (Carlton).","first-page":"539","article-title":"Roles of human liver type fatty acid binding protein in kidney disease clarified using hL-FABP chromosomal transgenic mice","volume":"16","author":"Kamijo-Ikemori A","year":"2011","unstructured":"Kamijo-Ikemori A, Sugaya T, Matsui K, Yokoyama T, Kimura K. Roles of human liver type fatty acid binding protein in kidney disease clarified using hL-FABP chromosomal transgenic mice. Nephrology (Carlton). 2011;16(6):539\u2013544."},{"key":"bib24","series-title":"Eur J Pharmacol.","first-page":"88","article-title":"Renoprotective effect of the xanthine oxidoreductase inhibitor Topiroxostat under decreased angiotensfin II type 1 a receptor expression","volume":"815","author":"Ohata K","year":"2017","unstructured":"Ohata K, Kamijo-Ikemori A, Sugaya T, et al. Renoprotective effect of the xanthine oxidoreductase inhibitor Topiroxostat under decreased angiotensfin II type 1 a receptor expression. Eur J Pharmacol. 2017;815:88\u201397."},{"issue":"3","key":"bib25","series-title":"Nephrology (Carlton).","first-page":"117","article-title":"Urinary liver-type fatty acid binding protein is a biomarker reflecting renal damage and the ameliorative effect of drugs at an early stage of histone-induced acute kidney injury","volume":"29","author":"Ohata K","year":"2024","unstructured":"Ohata K, Sugaya T, Nguyen HN, et al. Urinary liver-type fatty acid binding protein is a biomarker reflecting renal damage and the ameliorative effect of drugs at an early stage of histone-induced acute kidney injury. Nephrology (Carlton). 2024;29(3):117\u2013125."},{"issue":"12","key":"bib26","series-title":"J Lipid Res.","first-page":"2238","article-title":"Recent insights into the biological functions of liver fatty acid binding protein 1","volume":"56","author":"Wang GQ","year":"2015","unstructured":"Wang GQ, Bonkovsky HL, Lemos A, Burczynsk FJ. Recent insights into the biological functions of liver fatty acid binding protein 1. J Lipid Res. 2015;56(12):2238\u20132247."},{"issue":"5","key":"bib27","series-title":"Hepatology.","first-page":"1191","article-title":"Protection against Western diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice","volume":"44","author":"Newberry EP","year":"2006","unstructured":"Newberry EP, Xie Y, Kennedy SM, Luo J, Davidson NO. Protection against Western diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice. Hepatology. 2006;44(5):1191\u20131205."},{"issue":"4","key":"bib28","series-title":"J Lipid Res.","first-page":"744","article-title":"Decreased body weight and hepatic steatosis with altered fatty acid ethanolamide metabolism in aged L-Fabp -\/- mice","volume":"53","author":"Newberry EP","year":"2012","unstructured":"Newberry EP, Kennedy SM, Xie Y, et al. Decreased body weight and hepatic steatosis with altered fatty acid ethanolamide metabolism in aged L-Fabp -\/- mice. J Lipid Res. 2012;53(4):744\u2013754."},{"key":"bib29","year":"1985","unstructured":"NIH. Guide for the Care and Use of Laboratory Animals. NIH Publication No. 86-23. Department of Health and Human Services; 1985."},{"issue":"2","key":"bib30","series-title":"PLoS One.","first-page":"e88584","article-title":"Effect of diet on expression of genes involved in lipid metabolism, oxidative stress, and inflammation in mouse liver-insights into mechanisms of hepatic steatosis","volume":"9","author":"Renaud HJ","year":"2014","unstructured":"Renaud HJ, Cui JY, Lu H, Klaassen CD. Effect of diet on expression of genes involved in lipid metabolism, oxidative stress, and inflammation in mouse liver-insights into mechanisms of hepatic steatosis. PLoS One. 2014;9(2):e88584."},{"issue":"1\u20132","key":"bib31","series-title":"Mol Cell Biochem.","first-page":"167","article-title":"Fatty acid-binding protein expression in the liver: its regulation and relationship to the zonation of fatty acid metabolism","volume":"98","author":"Bass NM","year":"1990","unstructured":"Bass NM. Fatty acid-binding protein expression in the liver: its regulation and relationship to the zonation of fatty acid metabolism. Mol Cell Biochem. 1990;98(1\u20132):167\u2013176."},{"issue":"6","key":"bib32","series-title":"Am J Pathol.","first-page":"958","article-title":"Impaired hepatic very low-density lipoprotein secretion promotes tumorigenesis and is accelerated with Fabp1 deletion","volume":"194","author":"Newberry EP","year":"2024","unstructured":"Newberry EP, Molitor EA, Liu A, et al. Impaired hepatic very low-density lipoprotein secretion promotes tumorigenesis and is accelerated with Fabp1 deletion. Am J Pathol. 2024;194(6):958\u2013974."},{"issue":"11","key":"bib33","series-title":"J Am Soc Nephrol.","first-page":"2894","article-title":"Renal L-type fatty acid\u2013binding protein in acute ischemic injury","volume":"18","author":"Yamamoto T","year":"2007","unstructured":"Yamamoto T, Noiri E, Ono Y, et al. Renal L-type fatty acid\u2013binding protein in acute ischemic injury. J Am Soc Nephrol. 2007;18(11):2894\u20132902."},{"issue":"12","key":"bib34","series-title":"J Vet Med Sci.","first-page":"1868","article-title":"Temporal changes in urinary excretion of liver-type fatty acid binding protein (L-FABP) in acute kidney injury model of domestic cats: a preliminary study","volume":"81","author":"Katayama M","year":"2019","unstructured":"Katayama M, Miyazaki T, Ohata K, et al. Temporal changes in urinary excretion of liver-type fatty acid binding protein (L-FABP) in acute kidney injury model of domestic cats: a preliminary study. J Vet Med Sci. 2019;81(12):1868\u20131872."},{"issue":"1","key":"bib35","series-title":"Ren Replace Ther.","first-page":"26","article-title":"Urinary excretion of liver-type fatty acid-binding protein reflects the severity of sepsis","volume":"3","author":"Sato E","year":"2017","unstructured":"Sato E, Kamijo-Ikemori A, Oikawa T, et al. Urinary excretion of liver-type fatty acid-binding protein reflects the severity of sepsis. Ren Replace Ther. 2017;3(1):26."},{"key":"bib36","series-title":"Eur J Med Chem.","first-page":"116358","article-title":"Design, synthesis, and biological evaluation of first-in-class FABP1 inhibitors for the treatment of NASH","volume":"270","author":"Chen Y","year":"2024","unstructured":"Chen Y, Yu M, Chen L, et al. Design, synthesis, and biological evaluation of first-in-class FABP1 inhibitors for the treatment of NASH. Eur J Med Chem. 2024;270:116358."},{"issue":"3","key":"bib37","series-title":"J Lipid Res.","first-page":"416","article-title":"Perilipin 5 and liver fatty acid binding protein function to restore quiescence in mouse hepatic stellate cells","volume":"59","author":"Lin J","year":"2018","unstructured":"Lin J, Zheng S, Attie AD, et al. Perilipin 5 and liver fatty acid binding protein function to restore quiescence in mouse hepatic stellate cells. J Lipid Res. 2018;59(3):416\u2013428."},{"issue":"14","key":"bib38","series-title":"Oncotarget.","first-page":"18229","article-title":"Liver fatty acid-binding protein (L-FABP) promotes cellular angiogenesis and migration in hepatocellular carcinoma","volume":"7","author":"Ku CY","year":"2016","unstructured":"Ku CY, Liu YH, Lin HY, Lu SC, Lin JY. Liver fatty acid-binding protein (L-FABP) promotes cellular angiogenesis and migration in hepatocellular carcinoma. Oncotarget. 2016;7(14):18229\u201318246."},{"issue":"4","key":"bib1","series-title":"J Hepatol.","first-page":"896","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030","volume":"69","author":"Estes C","year":"2018","unstructured":"Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J Hepatol. 2018;69(4):896\u2013904."},{"key":"bib2","series-title":"Metabolism.","first-page":"155835","article-title":"Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges","volume":"154","author":"Kokkorakis M","year":"2024","unstructured":"Kokkorakis M, Boutari C, Hill MA, et al. Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges. Metabolism. 2024;154:155835."},{"issue":"1\u20132","key":"bib3","series-title":"Mol Cell Biochem.","first-page":"225","article-title":"Liver fatty acid-binding protein in two cases of human lipid storage","volume":"98","author":"Vergani L","year":"1990","unstructured":"Vergani L, Fanin M, Martinuzzi A, et al. Liver fatty acid-binding protein in two cases of human lipid storage. Mol Cell Biochem. 1990;98(1\u20132):225\u2013230."},{"issue":"4","key":"bib4","series-title":"Hepatology.","first-page":"871","article-title":"Antioxidative function of L-FABP in L-FABP stable transfected Chang liver cells","volume":"42","author":"Wang G","year":"2005","unstructured":"Wang G, Gong Y, Anderson J, et al. Antioxidative function of L-FABP in L-FABP stable transfected Chang liver cells. Hepatology. 2005;42(4):871\u2013879."},{"issue":"1","key":"bib5","series-title":"Eur J Pharmacol.","first-page":"61","article-title":"Expression and antioxidant function of liver fatty acid binding protein in normal and bile-duct ligated rats","volume":"560","author":"Wang G","year":"2007","unstructured":"Wang G, Shen H, Rajaraman G, et al. Expression and antioxidant function of liver fatty acid binding protein in normal and bile-duct ligated rats. Eur J Pharmacol. 2007;560(1):61\u201368."},{"issue":"125","key":"bib6","series-title":"Hepatogastroenterology.","first-page":"1095","article-title":"Serum liver fatty acid binding protein shows good correlation with liver histology in NASH","volume":"60","author":"\u00d6zenirler S","year":"2013","unstructured":"\u00d6zenirler S, Degertekin CK, Erkan G, et al. Serum liver fatty acid binding protein shows good correlation with liver histology in NASH. Hepatogastroenterology. 2013;60(125):1095\u20131100."},{"issue":"1-2","key":"bib7","series-title":"Wien Klin Wochenschr.","first-page":"48","article-title":"Liver fatty acid-binding protein as a diagnostic marker for non-alcoholic fatty liver disease","volume":"128","author":"Akbal E","year":"2016","unstructured":"Akbal E, Ko\u00e7ak E, Aky\u00fcrek O, K\u00f6kl\u00fc S, Batgi H, \u015eenes M. Liver fatty acid-binding protein as a diagnostic marker for non-alcoholic fatty liver disease. Wien Klin Wochenschr. 2016;128(1-2):48\u201352."},{"issue":"2","key":"bib8","series-title":"Int J Med Sci.","first-page":"182","article-title":"Circulating fatty acid-binding protein 1 (FABP1) and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus","volume":"17","author":"Lu Y-C","year":"2020","unstructured":"Lu Y-C, Chang C-C, Wang C-P, et al. Circulating fatty acid-binding protein 1 (FABP1) and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Int J Med Sci. 2020;17(2):182\u2013190."},{"issue":"1","key":"bib9","series-title":"Arch Med Res.","first-page":"34","article-title":"Liver fatty acid-binding protein is a diagnostic marker to detect liver injury due to chronic hepatitis C infection","volume":"44","author":"Akbal E","year":"2013","unstructured":"Akbal E, K\u00f6kl\u00fc S, Ko\u00e7ak E, et al. Liver fatty acid-binding protein is a diagnostic marker to detect liver injury due to chronic hepatitis C infection. Arch Med Res. 2013;44(1):34\u201338."},{"issue":"2","key":"bib10","series-title":"J Hepatol.","first-page":"337","article-title":"Randomized controlled trial analyzing the effect of 15 or 30 min intermittent Pringle maneuver on hepatocellular damage during liver surgery","volume":"55","author":"van den Broek MA","year":"2011","unstructured":"van den Broek MA, Bloemen JG, Dello SA, van de Poll MC, Olde Damink SW, Dejong CH. Randomized controlled trial analyzing the effect of 15 or 30 min intermittent Pringle maneuver on hepatocellular damage during liver surgery. J Hepatol. 2011;55(2):337\u2013345."},{"issue":"11","key":"bib11","series-title":"Clin Chem.","first-page":"2055","article-title":"Liver fatty acid-binding protein as a sensitive serum marker of acute hepatocellular damage in liver transplant recipients","volume":"48","author":"Pelsers MM","year":"2002","unstructured":"Pelsers MM, Morovat A, Alexander GJ, Hermens WT, Trull AK, Glatz JF. Liver fatty acid-binding protein as a sensitive serum marker of acute hepatocellular damage in liver transplant recipients. Clin Chem. 2002;48(11):2055\u20132057."},{"issue":"2","key":"bib12","series-title":"Hepatology.","first-page":"760","article-title":"Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort","volume":"69","author":"Church RJ","year":"2019","unstructured":"Church RJ, Kullak-Ublick GA, Aubrecht J, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort. Hepatology. 2019;69(2):760\u2013773."},{"issue":"3","key":"bib13","series-title":"Hepatology.","first-page":"938","article-title":"Elevated FABP1 serum levels are associated with poorer survival in acetaminophen-induced acute liver failure","volume":"65","author":"Karvellas CJ","year":"2017","unstructured":"Karvellas CJ, Speiser JL, Tremblay M, Lee WM, Rose CF, Group U, US Acute Liver Failure Study Group. Elevated FABP1 serum levels are associated with poorer survival in acetaminophen-induced acute liver failure. Hepatology. 2017;65(3):938\u2013949."},{"issue":"6","key":"bib14","series-title":"Hepatol Commun.","first-page":"825","article-title":"Serum liver-type fatty acid-binding protein is a possible prognostic factor in human chronic liver diseases from chronic hepatitis to liver cirrhosis and hepatocellular carcinoma","volume":"3","author":"Eguchi A","year":"2019","unstructured":"Eguchi A, Hasegawa H, Iwasa M, et al. Serum liver-type fatty acid-binding protein is a possible prognostic factor in human chronic liver diseases from chronic hepatitis to liver cirrhosis and hepatocellular carcinoma. Hepatol Commun. 2019;3(6):825\u2013837."},{"issue":"1","key":"bib15","series-title":"Pharm Res.","first-page":"89","article-title":"The role of elevated liver-type fatty acid-binding proteins in liver diseases","volume":"38","author":"Eguchi A","year":"2021","unstructured":"Eguchi A, Iwasa M. The role of elevated liver-type fatty acid-binding proteins in liver diseases. Pharm Res. 2021;38(1):89\u201395."},{"issue":"1","key":"bib16","series-title":"Transplant Proc.","first-page":"413","article-title":"Liver fatty acid-binding protein: an early and sensitive plasma marker of hepatocellular damage and a reliable predictor of graft viability after liver transplantation from non-heart-beating donors","volume":"37","author":"Monbaliu D","year":"2005","unstructured":"Monbaliu D, de Vries B, Crabb\u00e9 T, et al. Liver fatty acid-binding protein: an early and sensitive plasma marker of hepatocellular damage and a reliable predictor of graft viability after liver transplantation from non-heart-beating donors. Transplant Proc. 2005;37(1):413\u2013416."},{"issue":"2","key":"bib17","series-title":"Curr Health Sci J.","first-page":"115","article-title":"Liver fatty acid binding protein and hemojuvelin - potential biomarkers for liver function in rat model","volume":"41","author":"Bogdan M","year":"2015","unstructured":"Bogdan M, Silosi I, Surlin P, et al. Liver fatty acid binding protein and hemojuvelin - potential biomarkers for liver function in rat model. Curr Health Sci J. 2015;41(2):115\u2013120."},{"issue":"3","key":"bib18","series-title":"J Appl Toxicol.","first-page":"516","article-title":"Serum biomarkers of isoniazid-induced liver injury: aminotransferases are insufficient, and OPN, L-FABP and HMGB1 can be promising novel biomarkers","volume":"42","author":"Cheng X","year":"2022","unstructured":"Cheng X, Zhu J-L, Li Y, et al. Serum biomarkers of isoniazid-induced liver injury: aminotransferases are insufficient, and OPN, L-FABP and HMGB1 can be promising novel biomarkers. J Appl Toxicol. 2022;42(3):516\u2013528."},{"issue":"2","key":"bib19","series-title":"Int J Exp Pathol.","first-page":"93","article-title":"An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis","volume":"94","author":"Matsumoto M","year":"2013","unstructured":"Matsumoto M, Hada N, Sakamaki Y, et al. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. Int J Exp Pathol. 2013;94(2):93\u2013103."},{"issue":"4","key":"bib20","series-title":"Int J Exp Pathol.","first-page":"221","article-title":"Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet","volume":"98","author":"Ikawa-Yoshida A","year":"2017","unstructured":"Ikawa-Yoshida A, Matsuo S, Kato A, et al. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet. Int J Exp Pathol. 2017;98(4):221\u2013233."},{"issue":"4","key":"bib21","series-title":"Am J Pathol.","first-page":"1243","article-title":"Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules","volume":"165","author":"Kamijo A","year":"2004","unstructured":"Kamijo A, Sugaya T, Hikawa A, et al. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol. 2004;165(4):1243\u20131255."},{"issue":"4","key":"bib22","series-title":"Am J Physiol Renal Physiol.","first-page":"F669","article-title":"Urinary fatty acid-binding protein 1: an early predictive biomarker of kidney injury","volume":"296","author":"Noiri E","year":"2009","unstructured":"Noiri E, Doi K, Negishi K, et al. Urinary fatty acid-binding protein 1: an early predictive biomarker of kidney injury. Am J Physiol Renal Physiol. 2009;296(4):F669\u2013F679."},{"issue":"6","key":"bib23","series-title":"Nephrology (Carlton).","first-page":"539","article-title":"Roles of human liver type fatty acid binding protein in kidney disease clarified using hL-FABP chromosomal transgenic mice","volume":"16","author":"Kamijo-Ikemori A","year":"2011","unstructured":"Kamijo-Ikemori A, Sugaya T, Matsui K, Yokoyama T, Kimura K. Roles of human liver type fatty acid binding protein in kidney disease clarified using hL-FABP chromosomal transgenic mice. Nephrology (Carlton). 2011;16(6):539\u2013544."},{"key":"bib24","series-title":"Eur J Pharmacol.","first-page":"88","article-title":"Renoprotective effect of the xanthine oxidoreductase inhibitor Topiroxostat under decreased angiotensfin II type 1 a receptor expression","volume":"815","author":"Ohata K","year":"2017","unstructured":"Ohata K, Kamijo-Ikemori A, Sugaya T, et al. Renoprotective effect of the xanthine oxidoreductase inhibitor Topiroxostat under decreased angiotensfin II type 1 a receptor expression. Eur J Pharmacol. 2017;815:88\u201397."},{"issue":"3","key":"bib25","series-title":"Nephrology (Carlton).","first-page":"117","article-title":"Urinary liver-type fatty acid binding protein is a biomarker reflecting renal damage and the ameliorative effect of drugs at an early stage of histone-induced acute kidney injury","volume":"29","author":"Ohata K","year":"2024","unstructured":"Ohata K, Sugaya T, Nguyen HN, et al. Urinary liver-type fatty acid binding protein is a biomarker reflecting renal damage and the ameliorative effect of drugs at an early stage of histone-induced acute kidney injury. Nephrology (Carlton). 2024;29(3):117\u2013125."},{"issue":"12","key":"bib26","series-title":"J Lipid Res.","first-page":"2238","article-title":"Recent insights into the biological functions of liver fatty acid binding protein 1","volume":"56","author":"Wang GQ","year":"2015","unstructured":"Wang GQ, Bonkovsky HL, Lemos A, Burczynsk FJ. Recent insights into the biological functions of liver fatty acid binding protein 1. J Lipid Res. 2015;56(12):2238\u20132247."},{"issue":"5","key":"bib27","series-title":"Hepatology.","first-page":"1191","article-title":"Protection against Western diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice","volume":"44","author":"Newberry EP","year":"2006","unstructured":"Newberry EP, Xie Y, Kennedy SM, Luo J, Davidson NO. Protection against Western diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice. Hepatology. 2006;44(5):1191\u20131205."},{"issue":"4","key":"bib28","series-title":"J Lipid Res.","first-page":"744","article-title":"Decreased body weight and hepatic steatosis with altered fatty acid ethanolamide metabolism in aged L-Fabp -\/- mice","volume":"53","author":"Newberry EP","year":"2012","unstructured":"Newberry EP, Kennedy SM, Xie Y, et al. Decreased body weight and hepatic steatosis with altered fatty acid ethanolamide metabolism in aged L-Fabp -\/- mice. J Lipid Res. 2012;53(4):744\u2013754."},{"key":"bib29","year":"1985","unstructured":"NIH. Guide for the Care and Use of Laboratory Animals. NIH Publication No. 86-23. Department of Health and Human Services; 1985."},{"issue":"2","key":"bib30","series-title":"PLoS One.","first-page":"e88584","article-title":"Effect of diet on expression of genes involved in lipid metabolism, oxidative stress, and inflammation in mouse liver-insights into mechanisms of hepatic steatosis","volume":"9","author":"Renaud HJ","year":"2014","unstructured":"Renaud HJ, Cui JY, Lu H, Klaassen CD. Effect of diet on expression of genes involved in lipid metabolism, oxidative stress, and inflammation in mouse liver-insights into mechanisms of hepatic steatosis. PLoS One. 2014;9(2):e88584."},{"issue":"1\u20132","key":"bib31","series-title":"Mol Cell Biochem.","first-page":"167","article-title":"Fatty acid-binding protein expression in the liver: its regulation and relationship to the zonation of fatty acid metabolism","volume":"98","author":"Bass NM","year":"1990","unstructured":"Bass NM. Fatty acid-binding protein expression in the liver: its regulation and relationship to the zonation of fatty acid metabolism. Mol Cell Biochem. 1990;98(1\u20132):167\u2013176."},{"issue":"6","key":"bib32","series-title":"Am J Pathol.","first-page":"958","article-title":"Impaired hepatic very low-density lipoprotein secretion promotes tumorigenesis and is accelerated with Fabp1 deletion","volume":"194","author":"Newberry EP","year":"2024","unstructured":"Newberry EP, Molitor EA, Liu A, et al. Impaired hepatic very low-density lipoprotein secretion promotes tumorigenesis and is accelerated with Fabp1 deletion. Am J Pathol. 2024;194(6):958\u2013974."},{"issue":"11","key":"bib33","series-title":"J Am Soc Nephrol.","first-page":"2894","article-title":"Renal L-type fatty acid\u2013binding protein in acute ischemic injury","volume":"18","author":"Yamamoto T","year":"2007","unstructured":"Yamamoto T, Noiri E, Ono Y, et al. Renal L-type fatty acid\u2013binding protein in acute ischemic injury. J Am Soc Nephrol. 2007;18(11):2894\u20132902."},{"issue":"12","key":"bib34","series-title":"J Vet Med Sci.","first-page":"1868","article-title":"Temporal changes in urinary excretion of liver-type fatty acid binding protein (L-FABP) in acute kidney injury model of domestic cats: a preliminary study","volume":"81","author":"Katayama M","year":"2019","unstructured":"Katayama M, Miyazaki T, Ohata K, et al. Temporal changes in urinary excretion of liver-type fatty acid binding protein (L-FABP) in acute kidney injury model of domestic cats: a preliminary study. J Vet Med Sci. 2019;81(12):1868\u20131872."},{"issue":"1","key":"bib35","series-title":"Ren Replace Ther.","first-page":"26","article-title":"Urinary excretion of liver-type fatty acid-binding protein reflects the severity of sepsis","volume":"3","author":"Sato E","year":"2017","unstructured":"Sato E, Kamijo-Ikemori A, Oikawa T, et al. Urinary excretion of liver-type fatty acid-binding protein reflects the severity of sepsis. Ren Replace Ther. 2017;3(1):26."},{"key":"bib36","series-title":"Eur J Med Chem.","first-page":"116358","article-title":"Design, synthesis, and biological evaluation of first-in-class FABP1 inhibitors for the treatment of NASH","volume":"270","author":"Chen Y","year":"2024","unstructured":"Chen Y, Yu M, Chen L, et al. Design, synthesis, and biological evaluation of first-in-class FABP1 inhibitors for the treatment of NASH. Eur J Med Chem. 2024;270:116358."},{"issue":"3","key":"bib37","series-title":"J Lipid Res.","first-page":"416","article-title":"Perilipin 5 and liver fatty acid binding protein function to restore quiescence in mouse hepatic stellate cells","volume":"59","author":"Lin J","year":"2018","unstructured":"Lin J, Zheng S, Attie AD, et al. Perilipin 5 and liver fatty acid binding protein function to restore quiescence in mouse hepatic stellate cells. J Lipid Res. 2018;59(3):416\u2013428."},{"issue":"14","key":"bib38","series-title":"Oncotarget.","first-page":"18229","article-title":"Liver fatty acid-binding protein (L-FABP) promotes cellular angiogenesis and migration in hepatocellular carcinoma","volume":"7","author":"Ku CY","year":"2016","unstructured":"Ku CY, Liu YH, Lin HY, Lu SC, Lin JY. Liver fatty acid-binding protein (L-FABP) promotes cellular angiogenesis and migration in hepatocellular carcinoma. Oncotarget. 2016;7(14):18229\u201318246."}],"container-title":["Journal of the American Association for Laboratory Animal Science"],"original-title":[],"link":[{"URL":"https:\/\/aalas.kglmeridian.com\/view\/journals\/72010024\/64\/5\/article-p952.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/aalas.kglmeridian.com\/downloadpdf\/journals\/72010024\/64\/5\/article-p952.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aalas.kglmeridian.com\/downloadpdf\/journals\/72010024\/64\/5\/article-p952.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T02:40:41Z","timestamp":1774406441000},"score":1,"resource":{"primary":{"URL":"https:\/\/aalas.kglmeridian.com\/view\/journals\/72010024\/64\/5\/article-p952.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":76,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.30802\/aalas-jaalas-25-003","relation":{},"ISSN":["1559-6109"],"issn-type":[{"value":"1559-6109","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}